Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

Br J Haematol. 2017 Jun;177(5):808-813. doi: 10.1111/bjh.14103. Epub 2016 Apr 13.

Authors

Xia Liu^{1

2}, Zachary R Hunter^{1

2}, Lian Xu¹, Jie Chen¹, Jiaji G Chen¹, Nicholas Tsakmaklis¹, Christopher J Patterson¹, Jorge J Castillo^{1

2}, Sara Buhrlage³, Nathanael Gray³, Steven P Treon^{1

2}, Guang Yang^{1

2}

Affiliations

¹ Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA.
² Department of Medicine, Harvard Medical School, Boston, MA, USA.
³ Department of Cancer Biology, Harvard Medical School, Boston, MA, USA.

PMID: 27073043
DOI: 10.1111/bjh.14103

No abstract available

Keywords: BTK; IRAK1; MYD88; NFκB; Waldenström macroglobulinaemia.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / chemistry
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Drug Discovery
Humans
Models, Molecular
Molecular Conformation
Molecular Targeted Therapy
Mutation
Myeloid Differentiation Factor 88 / antagonists & inhibitors*
Myeloid Differentiation Factor 88 / chemistry
Myeloid Differentiation Factor 88 / genetics
Myeloid Differentiation Factor 88 / metabolism*
Peptide Fragments / chemistry
Peptide Fragments / pharmacology
Peptide Fragments / therapeutic use
Protein Binding
Protein Interaction Domains and Motifs
Protein Multimerization / drug effects
Signal Transduction / drug effects
Structure-Activity Relationship
Waldenstrom Macroglobulinemia / drug therapy
Waldenstrom Macroglobulinemia / genetics
Waldenstrom Macroglobulinemia / metabolism*

Substances

Antineoplastic Agents
Myeloid Differentiation Factor 88
Peptide Fragments